enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Buy” by Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned an average rating of “Buy” from the seven analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $19.50.

Several brokerages have commented on ENGN. Morgan Stanley lowered their price objective on shares of enGene from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, September 12th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of enGene in a research report on Monday, September 8th.

enGene Stock Up 11.3%

Shares of ENGN opened at $7.60 on Thursday. enGene has a one year low of $2.65 and a one year high of $11.00. The company has a market cap of $389.04 million, a P/E ratio of -4.00 and a beta of -0.28. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.34 and a quick ratio of 10.34. The firm has a 50 day simple moving average of $4.90 and a two-hundred day simple moving average of $4.23.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Research analysts forecast that enGene will post -1.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ENGN. Affinity Asset Advisors LLC acquired a new position in shares of enGene during the second quarter worth $280,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of enGene by 2.7% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company’s stock worth $7,041,000 after buying an additional 41,874 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in shares of enGene during the first quarter worth $107,000. Jane Street Group LLC acquired a new position in shares of enGene during the fourth quarter worth $93,000. Finally, Paloma Partners Management Co acquired a new position in shares of enGene during the second quarter worth $38,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.